Last reviewed · How we verify
Maribavir Commercial Tablet Formulation
Maribavir Commercial Tablet Formulation is a Small molecule drug developed by Takeda. It is currently in Phase 1 development. Also known as: TAK-620.
At a glance
| Generic name | Maribavir Commercial Tablet Formulation |
|---|---|
| Also known as | TAK-620 |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maribavir Commercial Tablet Formulation CI brief — competitive landscape report
- Maribavir Commercial Tablet Formulation updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about Maribavir Commercial Tablet Formulation
What is Maribavir Commercial Tablet Formulation?
Maribavir Commercial Tablet Formulation is a Small molecule drug developed by Takeda.
Who makes Maribavir Commercial Tablet Formulation?
Maribavir Commercial Tablet Formulation is developed by Takeda (see full Takeda pipeline at /company/takeda).
Is Maribavir Commercial Tablet Formulation also known as anything else?
Maribavir Commercial Tablet Formulation is also known as TAK-620.
What development phase is Maribavir Commercial Tablet Formulation in?
Maribavir Commercial Tablet Formulation is in Phase 1.
Related
- Manufacturer: Takeda — full pipeline
- Also known as: TAK-620
- Compare: Maribavir Commercial Tablet Formulation vs similar drugs
- Pricing: Maribavir Commercial Tablet Formulation cost, discount & access